Experimental drug shows promise in slowing duchenne muscle loss
NCT ID NCT04433234
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests the long-term safety and effectiveness of an experimental drug called DS-5141b (Renadirsen) in 8 people with Duchenne muscular dystrophy who have already completed a previous study. Participants receive a weekly injection under the skin. Researchers will monitor side effects and measure changes in walking, muscle strength, and breathing over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS-5141b (Renadirsen), given as a weekly injection under the skin
What this could lead to
If successful, this could point toward a treatment that slows muscle decline and helps maintain walking ability in Duchenne muscular dystrophy.
What could go wrong
This is a very small, early-phase study with only 8 participants, so results may not apply to all patients. Long-term safety and effectiveness are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kobe University Hospital
Hyōgo, 650-0017, Japan
-
National Center of Neurology and Psychiatry
Tokyo, Kodaira-Shi, 187-8551, Japan